The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization

References

• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449–6465
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999; 1: 197–207
   PubMedGoogle Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14: 198–206
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metast Rev 1987; 5: 313–341
   PubMed Web of Science ®Google Scholar
• Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncol 2004; 9: 4–9
   Google Scholar
• Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 2001; 18: S243–259
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80: S57–64
   PubMed Web of Science ®Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev 1990; 9: 267–282
   PubMed Web of Science ®Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 2000; 57: 5–12
   PubMed Web of Science ®Google Scholar
• Gaya AM, Rustin GJ. Vascular disrupting agents: A new class of drug in cancer therapy. Clin Oncol (Royal College of Radiologists (Great Britain)) 2005; 17: 277–290
   Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415–427
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423–435
   PubMed Web of Science ®Google Scholar
• Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 1987; 50: 386–391
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189–195
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Entravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413–6422
   PubMed Web of Science ®Google Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829–1834
   PubMed Web of Science ®Google Scholar
• Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Rad Oncol Biol Phys 1998; 42: 899–903
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Rad Oncol Biol Phys 2002; 54: 1491–1496
   PubMed Web of Science ®Google Scholar
• Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Rad Oncol Biol Phys 1998; 42: 895–898
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520–11539
   PubMed Web of Science ®Google Scholar
• Overgaard J, Nielsen OS. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann N Y Acad Sci 1980; 335: 254–280
   PubMedGoogle Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977; 123: 511–514
   PubMed Web of Science ®Google Scholar
• Dahl O, Overgaard J. Hyperthermia. Oxford Textbook of Oncology, R Souhami, I Tannock, P Hohenberger, J Horiot. Oxford University Press, Oxford 2001; 511–525
   Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–790
   PubMed Web of Science ®Google Scholar
• Horsman MR. Overgaard J. Hyperthermia: A potent enhancer of Radiotherapy. Clin Oncol 2007, In press
   Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006; 22: 197–203
   PubMed Web of Science ®Google Scholar
• Pettit GR, Lippert JW III,. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000; 15: 203–216
   PubMedGoogle Scholar
• Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW III,, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004; 10: 1446–1453
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006; 12: 4090–4094
   PubMed Web of Science ®Google Scholar
• Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111: 604–610
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Rad Oncol Biol Phys 2001; 51: 1018–1024
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Rad Oncol Biol Phys 1980; 6: 1507–1517
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996; 12: 779–789
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Rad Oncol Biol Phys 2002; 54: 1518–1523
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497–503
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001; 17: 508–519
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001; 61: 313–320
   PubMed Web of Science ®Google Scholar
• Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL. Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Rad Res 2003; 160: 662–666
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Rad Res 2001; 156: 503–509
   PubMed Web of Science ®Google Scholar
• Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Rad Oncol Biol Phys 1998; 42: 905–908
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001; 60: 155–161
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Rad Oncol Biol Phys 2002; 53: 164–171
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Rad Oncol Biol Phys 2005; 62: 846–853
   PubMed Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005; 11: 835–842
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004; 20: 393–404
   PubMed Web of Science ®Google Scholar
• Frindel E, Malaise EP, Alpen E, Tubiana M. Kinetics of cell proliferation of an experimental tumor. Cancer Res 1967; 27: 1122–1131
   PubMed Web of Science ®Google Scholar
• Patterson DM, Rustin GJ. Vascular damaging agents. Clinical Oncol (Royal College of Radiologists (Great Britain)) 2007; 19: 443–456
   PubMed Web of Science ®Google Scholar